[bPhase III clinical trial plan for Rimatil has been submitted]
It is estimated that the mechanism of Nafamostat inhibits protease TMPRSS2, which is known to play a major role in the cell invasion process of COVID-19, and shows several hundred times more antiviral efficacy in human lung cell experiments compared to Remdesivir.
On the 30th, IND application for Rimatil (Bucillamine) which is marketed as a rheumatoid arthritis treatment was submitted to the FDA.
The Phase III clinical trial for Bucillamine is not directly controlled by Chong Kun Dang, but is hosted by the Canadian pharmaceutical bio company Revive Therapeutics.
Rimatil is a safe drug that has been sold in East Asian countries for over 30 years, and is a licensed-introduced drug from Santen company, Japan.
If the clinical trial phase III of Bucillamine is successful, Chong Kun Dang, which has exclusive domestic sales rights, will obtain COVID-19 treatment indication.
Bucillamine reported that N-Acetyl-L-cysteine significantly alleviates the symptoms of respiratory viral infections and produces significantly positive results in small-scale clinical trials in preclinical and COVID-19 mild patients.
According to Revive Therapeutics, the FDA has recommended the clinical phase III of COVID-19 treatment, Bucillamine, and will begin a full-scale clinical trial in the third quarter of this year.
Market Data 
Markets 
AI
